Welcome to the CURE blog.

/Blog/

Discount available on BIO 2018 registration

As a valued member of a state biotech association, we're offering you the opportunity to lock in a significant discount on two premier BIO 2018 registration packages: Convention Access and Convention Access & Partnering. Registration for BIO 2018 is not required at this point. Simply complete the form, and you will be sent your discount code prior to registration opening in late January 2018. Plus, BIO Members also receive complimentary session recordings following BIO 2018--a $300 value! MAKE HISTORY at BIO 2018 in Boston, MA. Complete the following form by Friday, January 19 to receive your discount code. link to [...]

By |January 10th, 2018|News|0 Comments

Intensity Therapeutics starts cancer treatment trial

Armed with a pair of U.S. patents and some $13 million in investments, Intensity Therapeutics Inc. in Westport has started clinical trials on what its founder maintains could be a game-changer in the treatment of cancer. “I looked at the problem from an engineer’s perspective,” said Lew Bender, Intensity Therapeutics president and CEO, at his biotech company’s 61 Wilton Road headquarters. “And what I wanted to do had three restrictions: killing big tumors without invasive surgery, getting rid of the small cancer cells that can’t be seen by the naked eye, and cutting back on the toxicity” associated with chemotherapy [...]

By |January 10th, 2018|News|0 Comments

Arvinas inks $830M licensing deal with Pfizer

New Haven biotech Arvinas LLC says it will collaborate with pharmaceutical giant Pfizer Inc. to develop a new class of drugs that attack disease-causing cellular proteins. The multi-year licensing agreement, potentially worth $830 million, is aimed at discovering and developing drugs to treat multiple diseases using Arvinas' PROTAC technology – small molecules that destroy harmful proteins. Based on research conducted at Yale University by Dr. Craig Crews, Arvinas' founder and chief scientific officer, PROTACs (short for proteolysis-targeting chimeras) are part of a new class of therapies focused on so-called protein degradation — which researchers say hold particular promise for cancer treatment. [...]

By |January 10th, 2018|News|0 Comments

Letter from the President of CURE

January 5, 2018 Dear CURE members: Thank you for being a member of CURE. I have had the pleasure of meeting many of you over the last couple of months and look forward to continuing to do so. My entire career has been spent supporting the bioscience industry in both for-profit and non-profit (Dawn’s Bio). I lived in the San Francisco Bay Area and watched the biotech industry grow from those early Genentech years to a dynamic engine of biotech today.  In my previous positions, I also covered San Diego, Washington, Florida, New Jersey, New York, and many other states, seeing [...]

By |January 10th, 2018|News|0 Comments

Loxo leads stock gains in SW Connecticut

After its shares rocketed up heading into the first weekend of June on news of positive clinical trial results, Loxo Oncology led all southwestern Connecticut companies for stock gains in 2017. The company is developing a drug to fight cancers that are uniquely dependent on abnormalities in specific genes. Shares of Stamford-based Loxo closed at $84.18 on Dec. 29, up from $32.12 at the end of 2016 for a 162 percent increase on the year more

By |January 10th, 2018|News|0 Comments

New JAX research re aging, canine cancer

The Jackson Laboratory (JAX) is beginning to work with top veterinary centers around the country. When a canine is diagnosed with a cancer of interest, its owner can opt to have the veterinarian donate their dog’s tumor. JAX will use the donated tumor to create a patient-derived xenograft (PDX) cancer model and sequence each tumor model ... more A major factor for increased susceptibility to disease in older people: The immune system declines with age. UConn Health gerontologist and aging researcher George Kuchel, M.D and Jackson Laboratory Professor and Director of Immunological Sciences Jacques Banchereau, Ph.D. have received funding from the [...]

By |January 10th, 2018|News|0 Comments

Achillion initiates Phase 1 re factor D inhibitor

Achillion Pharmaceuticals has begun dosing subjects in a first-in-human phase 1 trial of ACH-5228, a next-generation, oral small-molecule factor D inhibitor. "During 2017, we reported interim data from our on-going phase 2 clinical trials, in PNH and in C3G, which demonstrated that factor D inhibition represents a truly novel, first-in-class approach to potentially treating these devastating diseases," said Milind Deshpande, Ph.D., president and CEO of Achillion. more

By |January 10th, 2018|News|0 Comments

Six tech deals in 2017 cited as good for Connecticut

At least six big sales closed for Connecticut tech businesses in 2017, including the sale of Branford-based Core Infomatics to Thermo Fisher Scientific. "These six tech sales, all with a strong result for Connecticut, tell us there is a route to success and maybe we’ll see it,"writes Dan Haar in the CT Post. more

By |January 10th, 2018|News|0 Comments

Six tech deals in 2017 cited as good for Connecticut

At least six big sales closed for Connecticut tech businesses in 2017, including the sale of Branford-based Core Infomatics to Thermo Fisher Scientific. "These six tech sales, all with a strong result for Connecticut, tell us there is a route to success and maybe we’ll see it,"writes Dan Haar in the CT Post. more

By |January 2nd, 2018|News|0 Comments

Japan approves Alexion’s Soliris for gMC

Japan has approved Alexion's Soliris® (eculizumab) as a treatment for patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor antibody-positive and whose symptoms are difficult to control with high-dose intravenous immunoglobulin therapy or plasmapheresis. “This approval is great news for patients with gMG in Japan who fail to adequately respond to existing therapies and continue to face significant disease symptoms,” said Michiyo Sakurai, President of the Japanese Myasthenia Gravis Association, Kyoto, Japan. press release article in Hartford Business.com

By |January 2nd, 2018|News|0 Comments